Omeros Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMER research report →
Range $22 – $33
Price Chart
About the company
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates.
- CEO
- Gregory A. Demopulos
- IPO
- 2009
- Employees
- 175
- HQ
- Seattle, WA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a recovery regime after a deep drawdown, but it remains below its 200-day average at 13.77 and well under the 52-week high of 21.24. The longer-term setup is constructive only if it can hold above the mid-teens and rebuild momentum from the lower half of its yearly range.
Street sentiment is constructive, with a Buy consensus and a $27.50 median target versus a $15.39 pre-market quote. Recent action has tilted positive too: Cantor Fitzgerald upgraded to Overweight and reiterated that view, while H.C. Wainwright has kept a bullish stance through multiple target resets.
The earnings profile is volatile but not broken: Omeros has beaten in 5 of the last 8 quarters, yet the most recent print missed sharply at -$0.85 versus -$0.02 expected. Next-year EPS is modeled at $0.24, so shareholders should watch whether the company can stabilize execution and narrow losses after the latest miss.
The pattern leans negative on discretionary trading, with several officer and director sales alongside award and option-related activity. The clearest signal is selling from the VP of Finance, the General Counsel, and a director, while the CEO's large award and multiple exempt transactions look more like compensation mechanics than conviction buying.
Profitability is uneven: gross margin is 38.3%, but operating margin is -1.8953 and ROE is -5.7633. Revenue grew 14.9% year over year, yet operating cash flow was -$116.1 million and free cash flow was -$116.0 million, so the balance sheet and cash burn remain the key watchpoints.
As a clinical-stage biotech, Omeros trades on pipeline optionality rather than steady commercial scale, so it screens as more speculative than profitable peers. The valuation still reflects that gap: the market price sits below the $27.50 consensus target, leaving room if catalysts and execution improve.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $983.66M
- P/E
- 8.75
- Fwd P/E
- 16.01
- PEG
- 0.00
- P/S
- 13.55
- P/B
- -11.29
- EV/EBITDA
- 12.38
- Div Yield
- 0.00%
- Gross Margin
- 55.54%
- Op Margin
- -56.39%
- Net Margin
- 132.32%
- ROE
- -120.76%
- ROIC
- -19.34%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-122,796,000
- Net Income
- $-3,350,000+97.9%
- EPS
- $-0.05+98.0%
- OCF Growth
- +22.0%
- FCF Growth
- +22.0%
- 52W High
- $21.24
- 52W Low
- $6.70
- 50D MA
- $17.93
- 200D MA
- $13.83
- Beta
- 2.57
- RSI (14)
- 31
- Avg Volume
- 1.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Omeros reported continued early commercial momentum for YARTEMLEA, with strong quarter-over-quarter sales growth, positive operating cash flow, and management increasingly focused on expanding adoption and international access.· November 16, 2026
- YARTEMLEA posted $41.8 million of gross sales and $35.9 million of net sales in Q3, up 30% and 26% sequentially, respectively.
- Gross-to-net deductions rose to 14% from 11.5%, driven mainly by higher 340B utilization as more use shifted outpatient.
- The company reported GAAP net loss of $57.4 million, or $0.79 per share, versus net income of $13.2 million, or $0.18 per share, in Q2; non-GAAP adjusted net income was $4.7 million, or $0.06 per share.
- Omeros generated $13.3 million in cash from operations in the quarter, its second straight quarter of positive operating cash flow, and ended with $95.3 million in cash and investments.
- Management said YARTEMLEA uptake is broadening across transplant centers, with 109 unique accounts ordering the drug and P&T approvals at 80% of the top 40 U.S. transplant centers.
Third-quarter gross sales for YARTEMLEA were $41.8 million and net sales were $35.9 million, versus $32.2 million and $28.5 million in the second quarter. Gross-to-net deductions were 14% of gross sales, up from 11.5% in Q2, largely due to increased 340B sales. GAAP net loss was $57.4 million, or $0.79 per share, compared with net income of $13.2 million, or $0.18 per share, in Q2. Non-GAAP adjusted net income was $4.7 million, or $0.06 per share, versus $1.8 million, or $0.02 per share in Q2. The company ended the quarter with $95.3 million in cash and investments and generated $13.3 million in net cash from operating activities. For Q4 2026, management expects total operating expenses to be slightly higher than Q3, R&D to rise on YARTEMLEA and OMS805 spending, sales and marketing to increase with launch activity, interest expense to be about $6 million, and income from discontinued operations to be between $5 million and $6 million.
Greg Demopulos emphasized that YARTEMLEA’s launch is still in early stages but is gaining momentum, with adoption expanding across adult patients, outpatient settings, and more transplant centers. He framed the NTAP, pass-through status, and broader education push as important drivers of longer-term uptake, while repeatedly stressing that the company is seeing encouraging signs rather than giving firm near-term sales guidance. His tone was confident and constructive, especially around the product’s clinical value, reimbursement position, and potential to become standard of care.
David Borges focused on the financial improvement tied to the launch and the balance-sheet impact of the convertible note repurchases. He highlighted the swing in noncash mark-to-market on the 2029 notes, including a $62 million third-quarter noncash loss versus an $11.5 million net noncash gain in Q2, and noted that the company repurchased $30.5 million principal for $60.2 million, cutting outstanding principal to $40.3 million and lowering future cash interest expense. He also said contractual cash interest expense was $1.1 million in the quarter, cash and investments were $95.3 million, and the company produced $13.3 million of operating cash flow.
Analysts focused on launch pace, the effect of the new NTAP reimbursement, gross-to-net trends, per-patient utilization, and whether Omeros would be able to give 2027 guidance. Management said NTAP awareness is still developing and that education is a current focus, while suggesting more adoption should follow as hospitals and physicians learn how to use it. On gross-to-net, Greg Demopulos said the company has not given a target but thinks it is approaching the upper range faster than expected and mentioned a possible high-teens level over time. He also said the company likely will not provide 2027 guidance until it has more operating data, despite being pleased with current momentum.
The bull case from this call is that YARTEMLEA is gaining traction quickly in its second full quarter of sales, with broadening account penetration, more adult use, and rising outpatient adoption. Management also believes reimbursement is strengthening through NTAP, pass-through status, and improving payer coverage, while the drug’s clinical profile is helping drive willingness to treat outside the inpatient setting.
The main risks are that launch dynamics are still early, reimbursement education is incomplete, and management is not ready to provide 2027 guidance because visibility remains limited. Gross-to-net is rising as 340B usage increases, and the company continues to face volatile noncash mark-to-market swings tied to the convertible notes. Internationally, the CHMP opinion was negative, and the European compassionate-use program is being closed to new patients, limiting near-term EU progress.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.7%
- Shares Outstanding
- 72.39M
- Float Shares
- 69.29M
of shares held by institutions
186 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.05M | ▲ 1.47K |
| Vanguard Group Inc | 4.01M | ▲ 666.36K |
| Ingalls & Snyder LLC | 3.10M | ▼ 564.20K |
| Vanguard Capital Management LLC | 3.06M | ▼ 13.95K |
| Ubs Group AG | 2.97M | ▼ 178.28K |
| State Street Corp | 2.24M | ▼ 79.00K |
| Geode Capital Management, LLC | 1.90M | ▼ 18.50K |
| Stifel Financial Corp | 1.84M | ▲ 1.21K |
| Federated Hermes, Inc. | 1.03M | ▲ 556.64K |
| Vanguard Portfolio Management LLC | 965.75K | ▲ 2.92K |
| Kotler Kevin | 905.63K | ▲ 905.63K |
| Rock Springs Capital Management LP | 847.21K | ▲ 128.71K |
Held by 210 ETFs
Biggest fund positions in OMER by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Demopulos Gregory A MD | other | 500,000 |
| Sep 22, 26 | Borges David J. | other | 5,000 |
| Sep 23, 26 | Borges David J. | other | 10,000 |
| Sep 22, 26 | Borges David J. | other | 5,000 |
| Sep 22, 26 | Borges David J. | other | 5,000 |
| Sep 23, 26 | Borges David J. | other | 10,000 |
| Sep 22, 26 | Borges David J. | other | 5,000 |
| Sep 23, 26 | Borges David J. | sell | 10,000 |
| Aug 28, 26 | Cancelmo Peter B | other | 25,000 |
| Aug 31, 26 | Cancelmo Peter B | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OMER coverage
Recent articles, reports, and earnings notes.

Omeros (OMER): YARTEMLEA Launch Drives a Buy Case
Omeros is transitioning from a development story to a commercial biotech as YARTEMLEA ramps quickly, but the stock still carries meaningful balance-sheet and execution risk. The launch momentum and improving cash flow support a Buy rating despite volatile GAAP results.

Omeros Corporation (OMER) slips despite deep earnings beat
Omeros Corporation (OMER) beat third-quarter EPS estimates, but shares slipped as a large GAAP loss and derivative mark-to-market charge overshadowed the results. This deep-dive analysis looks beyond the headline to Yartemlia growth, reimbursement progress, and what the quarter may signal for 2027.

Omeros Corporation (OMER) falls after earnings beats
Omeros Corporation (OMER) falls 14.6% as investors react to earnings beats, with shares under pressure despite the company topping expectations.
Want a deeper read on OMER?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Omeros: Yartemlea Commercial Momentum Supports Upgrade Despite Q3 Deceleration (Rating Upgrade)
seekingalpha.com · Nov 18
Omeros Q3 Earnings Call Highlights
marketbeat.com · Nov 16
Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 16
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 16
Omeros Corporation Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 16
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
globenewswire.com · Nov 10
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
businesswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice